See more : Anavex Life Sciences Corp. (0HFR.L) Income Statement Analysis – Financial Results
Complete financial analysis of Sigyn Therapeutics, Inc. (SIGY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sigyn Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TIL Limited (TIL.NS) Income Statement Analysis – Financial Results
- GlobalBlock Digital Asset Trading Limited (BLVDF) Income Statement Analysis – Financial Results
- IRSA Inversiones y Representaciones Sociedad Anónima (IRS-WT) Income Statement Analysis – Financial Results
- Life & Banc Split Corp. (LFBCF) Income Statement Analysis – Financial Results
- Gefran S.p.A. (GE.MI) Income Statement Analysis – Financial Results
Sigyn Therapeutics, Inc. (SIGY)
About Sigyn Therapeutics, Inc.
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 143.32K | 28.35K | 1.28M | 1.80M | 29.21K | 43.15K |
| Cost of Revenue | 8.86K | 10.45K | 536.05 | 11.30K | 35.67K | 9.71K | 512.38K | 1.03M | 9.93K | 25.25K |
| Gross Profit | -8.86K | -10.45K | -536.05 | -11.30K | 107.66K | 18.64K | 771.80K | 770.92K | 19.28K | 17.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 75.12% | 65.74% | 60.10% | 42.72% | 66.00% | 41.49% |
| Research & Development | 798.17K | 657.66K | 734.01K | 27.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.66M | 1.49M | 1.27M | 888.27K | 613.78K | 977.39K | 2.67M | 1.77M | 2.23M | 399.88K |
| Selling & Marketing | 392.00 | 457.00 | 0.00 | 705.00 | 11.83K | 45.95K | 533.45K | 795.82K | 42.99K | 5.57K |
| SG&A | 1.66M | 1.49M | 1.27M | 888.98K | 625.62K | 1.02M | 3.21M | 1.48M | 2.27M | 405.45K |
| Other Expenses | 0.00 | 0.00 | -536.05K | 0.00 | 0.00 | 105.27K | 3.21M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.46M | 2.15M | 2.01M | 916.43K | 625.62K | 1.02M | 3.21M | 1.48M | 2.27M | 405.45K |
| Cost & Expenses | 2.46M | 2.15M | 2.01M | 916.43K | 661.28K | 1.03M | 3.72M | 2.51M | 2.28M | 430.70K |
| Interest Income | 0.00 | 782.55 | 460.36 | 343.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.04M | 646.74K | 399.07K | 343.16K | 55.20K | 352.84K | 790.84K | 52.77K | 441.18K | 0.00 |
| Depreciation & Amortization | 8.86K | 10.45K | 19.15K | 11.30K | 75.33K | 247.39K | 235.79K | 86.46K | 1.16K | 0.00 |
| EBITDA | -2.45M | -2.14M | -2.53M | -905.13K | -442.63K | -1.70M | -2.82M | -549.42K | -691.62K | -387.54K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -308.84% | -2,671.50% | -171.20% | -34.56% | -7,710.39% | -898.05% |
| Operating Income | -2.46M | -2.15M | -2.01M | -916.43K | -517.96K | -1.00M | -2.43M | -710.20K | -2.25M | -387.54K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -361.39% | -3,544.18% | -189.56% | -39.36% | -7,714.35% | -898.05% |
| Total Other Income/Expenses | -1.69M | -782.55K | -996.40K | -343.16K | -2.80M | -1.30M | -1.41M | -121.33K | -80.13K | 0.00 |
| Income Before Tax | -4.15M | -2.93M | -3.00M | -1.26M | -3.31M | -2.30M | -4.25M | -831.53K | -2.69M | -387.54K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -2,311.58% | -8,129.24% | -330.99% | -46.08% | -9,224.88% | -898.05% |
| Income Tax Expense | 0.00 | 782.11K | 399.07K | 343.16K | -183.12K | 800.00 | 800.00 | 3.00 | 0.00 | 0.00 |
| Net Income | -4.15M | -3.71M | -3.40M | -1.60M | -3.13M | -2.62M | -4.25M | -831.53K | -2.69M | -387.54K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -2,183.82% | -9,243.24% | -331.05% | -46.08% | -9,224.88% | -898.05% |
| EPS | -3.77 | -3.97 | -0.09 | -0.22 | -5.78 | -6.04 | -13.54 | -114.92 | -11.77 | -2.08 |
| EPS Diluted | -3.77 | -3.97 | -0.09 | -0.22 | -5.78 | -6.04 | -13.54 | -114.92 | -11.77 | -2.08 |
| Weighted Avg Shares Out | 1.10M | 934.00K | 36.40M | 7.35M | 541.84K | 433.82K | 313.97K | 7.24K | 228.83K | 186.35K |
| Weighted Avg Shares Out (Dil) | 1.10M | 934.00K | 36.40M | 7.35M | 541.84K | 433.82K | 313.97K | 7.24K | 228.83K | 186.35K |
Sigyn Therapeutics™ to Present at Tomorrow's Emerging Growth Conference
Live Online Presentation Scheduled at 12 pm EST on March 6 th SAN DIEGO, CA, March 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OTCQB:”SIGY”), a development-stage medical technology company, announced today...
Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K
SAN DIEGO, CA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OTCQB: “SIGYD” – “SIGY”), a development-stage medical technology company, announced today the filing of its Form 10-K annual report with...
Sigyn Therapeutics Completes Reverse Stock Split
SAN DIEGO, CA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: “SIGYD”, “SIGY”), a development-stage medical technology company, disclosed today that a 1-for-40 reverse split of its common stock was implemented on...
Sigyn Therapeutics Announces Reverse Stock Split
SAN DIEGO, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced that a 1-for-40 reverse split of its common stock will be implemented...
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
SAN DIEGO, CA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the appointment of Jerry DeCiccio, CPA, MBA, as Chief Financial Officer.
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
SAN DIEGO, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announces financial results for the third quarter ended September 30, 2023.
Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
SAN DIEGO, CA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today disclosed the submission of a Patent Cooperation Treaty (PCT) application entitled: “ SYSTEM...
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results
SAN DIEGO, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a medical technology company that creates blood purification devices to overcome clearly defined limitations in healthcare, today announces financial results for the...
Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference
SAN DIEGO, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB:SIGY), a medical technology company that creates blood purification devices to overcome clearly defined limitations in healthcare, announced today that Jim...
Sigyn Therapeutics to Present at the Bullseye Small Cap Virtual Investor Conference
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-related conditions that precipitate sepsis, announced that its Chairman and CEO, Jim Joyce, will give a...
Source: https://incomestatements.info
Category: Stock Reports